Mdm2 and Tumorigenesis

Abstract

Since the discovery of Mdm2, the contribution of this RING E3 ubiquitin ligase to the pathobiology of cancer has focused almost exclusively on its role as a negative regulator of the p53 tumor suppressor. Under normal conditions, Mdm2 promotes the ubiquitin- and proteasome-dependent degradation of p53. Levels of p53 are thus kept sufficiently low to allow for cell survival and cell cycle progression. In the context of such insults as DNA damage or ribosomal stress, however, the Mdm2-p53 interaction is disrupted and p53 is stabilized. The myriad intracellular outcomes of p53 activation together comprise a robust program of tumor suppression that is short-circuited in cancer. Over half of all human malignancies are known to have lost p53 expression or sustained p53 mutation, whereas many of the remaining tumors harbor other alterations in key mediators of p53 activity that include overexpression of Mdm2. Therapies targeting the interaction between Mdm2 and p53 represent a possible means of pharmacologically reactivating the p53 pathway in this latter setting. The degree of overlap across the biological consequences of either p53 loss or Mdm2 overexpression, however, has not been thoroughly explored. Indeed, a body of evidence for several p53-independent functions of Mdm2 suggests that disrupting the Mdm2-p53 interaction may fail to address the full spectrum of oncogenic effects specific to tumors that overexpress Mdm2.

Keywords

Mdm2 p53 cancer tumorigenesis cell cycle

Introduction

The MDM2 gene was originally cloned from a spontaneously transformed mouse 3T3 cell line.¹ Molecular analysis revealed that the gene was heavily amplified in these cells. Early studies in cell culture demonstrated that Mdm2 overexpression rendered rodent fibroblasts tumorigenic in nude mice.^2,3 Since these initial reports, Mdm2 has been extensively described as a physiologic antagonist of p53, a role that has become central to its putative function as an oncogene.

Mdm2 binds the N-terminal of p53 and masks the transactivation domain required for p53 transcriptional activity.^4,5 Mdm2 also functions as a RING finger E3 ubiquitin ligase that targets p53 for degradation via the ubiquitin-proteasome system.^6-8 The RING finger further comprises a binding site for MdmX, a closely related heterodimerization partner of Mdm2 that has been reviewed elsewhere.⁹ Multiple cellular stresses are capable of disrupting the Mdm2-p53 interaction. Proteins involved in the DNA damage response can promote p53 stability and activation following genotoxic stress, for example, through a series of posttranslational modifications on both Mdm2 and p53.^10,11 In response to oncogenic signaling stress, the p14^ARF protein is transcriptionally upregulated and binds the central domain of Mdm2, impairing the ability of Mdm2 to regulate p53.¹² Similarly, nucleolar stress can result in the release of ribosomal proteins from the nucleolus, several of which have been shown to bind Mdm2 and stabilize p53 (Fig. 1).¹³

Figure 1.

The 491 amino acids that comprise the Mdm2 protein can be subdivided into an N-terminal p53 binding domain, a central acidic domain and adjacent zinc finger domain, and a C-terminal RING finger E3 ubiquitin ligase domain. There is considerable overlap across the N-terminal domain of Mdm2 that binds p53 and E2F1. Key regulators of Mdm2 activity, including ARF and ribosomal proteins, interact with Mdm2 at its acidic domain. Mdm2 has also been shown to require residues 254 to 264 in this region for its interaction with pRb.

When activated, p53 positively regulates Mdm2 expression.¹⁴ It has recently been proposed that phosphorylation of Mdm2 at serine 395, conferred by the ATM kinase in the setting of DNA damage, promotes allosteric remodeling of the Mdm2 RING domain, binding of p53 mRNA, and enhanced p53 protein translation.^15,16 The 2 proteins thus participate in an autoregulatory feedback loop that both restrains p53 function under normal conditions and drives p53 activation under stress. The importance of this interplay, at least from a development standpoint, is evidenced by the finding that MDM2^−/− mice die early in embryonic development but are rescued in a p53^−/− background.^17,18

These and additional data from human tumors collectively support an oncogenically relevant role for Mdm2 that rests on its ability to negatively regulate the stability and transcriptional activity of p53, thereby abrogating the tumor-suppressive effects of this pathway. Nevertheless, investigations in this field warrant reexamination. Methods employed to drive Mdm2 overexpression in cell culture, for example, have not yielded consistent results. Divergent experimental strategies have yielded data supporting discrepant conclusions regarding the role of Mdm2 in tumorigenesis that remain unresolved. These and other aspects of this work will be discussed in greater detail in the sections that follow.

Modeling Mdm2 Overexpression in Cells: Different Contexts, Different Methods, and Contradictory Conclusions

Initial studies of Mdm2 in cell culture suggested that Mdm2 was an oncogene.^2,3 These investigations employed a cosmid vector harboring the bacterial neo gene, mouse DHFR gene, and the full-length genomic equivalent of MDM2. By subjecting transfected cells to increasing doses of methotrexate, investigators were able to select for those clones that had coamplified MDM2 with DHFR. Stable clones of 3T3 and Rat2 cells overexpressing Mdm2 produced tumors in transplanted mice.² These tumors were subsequently shown to overexpress MDM2 by Northern blot analysis, but expression of Mdm2 protein was not assessed. Using the same approach, MDM2 overexpression was shown to cooperate with activated Ras in a series of transformation assays.³ Co-transfection of MDM2 and T24-ras in primary rat embryo fibroblasts (REFs) produced a 14-fold increase in the number of foci observed. In addition, REFs that had received both MDM2 and T24-ras could be cloned into stable lines, a feature not observed in REFs that received T24-ras alone.

Although these early findings en- dorsed an oncogenic role for Mdm2, several aspects of these studies merit further discussion. First, the number of foci observed in REFs that received both MDM2 and T24-ras was not equal to that observed in REFs that received both mutant p53 and T24-ras (28 vs. 45, respectively). These data suggest that at least certain effects of Mdm2 overexpression and p53 mutation may be nonredundant. Second, an association between endogenous rat p53 and transfected (murine) Mdm2 was not detected in transformed REFs. These findings further hinted that p53-independent functions of Mdm2 may play an important role in this model of transformation.

Results of more recent studies investigating the effects of Mdm2 overexpression in cells suggest that Mdm2 may be antiproliferative under certain circumstances (Table 1). Nontransformed human and rodent cells can select against Mdm2 expression in the formation of stable clones.¹⁹ The same effect has not been consistently observed in tumor lines, although the reasons for discrepancies between studies are not clear.⁷ Nevertheless, nontransformed cells transiently transfected with full-length Mdm2 cDNA arrest at G₀/G₁ when analyzed by flow cytometry, whereas tumor-derived cells do not.¹⁹ Through the use of deletion mutants, growth inhibitory domains of Mdm2 have been mapped to amino acid residues 155 to 220 (ID1) and 270 to 324 (ID2). The absence of one or both of these domains has been shown to enhance the tumorigenicity of transfected 3T3 cells in nude mice, and neither domain appears to be directly involved in the physical interaction of Mdm2 with p53.¹⁹ Mutations in ID2 have also been observed in MDM2 sequenced from human tumors in other studies.²⁰

Table 1.

Summary of Selected Studies of Mdm2 Overexpression in Cell Culture

Study	Overexpression Model	Cells Studied	Outcomes
Fakharzadeh et al., 1991²	Amplified genomic mdm2^a	Rat2, NIH 3T3	• 100% of nude mice receiving transfected cells developed tumors.
Finlay, 1993³	Amplified genomic mdm2^a	1° REFs	• Cells receiving Ras+Mdm2 showed an increase in foci and 100% clonability, and they formed tumors when injected into nude mice.
			• Co-transfection of Ras+Mdm2+wtp53 reduced the numbers of foci.
			• No interaction between transfected Mdm2 and endogenous p53 was observed.
Brown et al., 1998¹⁹	Mdm2 cDNA^b	NIH 3T3	• Nontransformed cells, but not tumor cell lines, failed to produce stable colonies expressing transfected Mdm2.
		1° MEFs	• Nontransformed cells, but not tumor cell lines, transfected with Mdm2 arrested in G₀/G₁.
		WI-38, U2OS, Saos-2, H1299, 21PT	• Putative antiproliferative effects of Mdm2 appeared to depend on domains of the protein distinct from that required for p53 interaction.
Kubbutat et al., 1997⁷	Mdm2 cDNA^b	U2OS, MCF7	• Wild-type Mdm2 could not be stably overexpressed in cell lines tested.
Dang et al., 2002²³	Mdm2 cDNA^c	MEFs, pre–B cells	• Cells that received full-length Mdm2 proliferated more rapidly and saturated at a higher density than empty-vector controls; the opposite was noted when truncated Mdm2 constructs lacking the p53 binding domain were used.

Refers to a cosmid vector containing amplified copies of mdm2 under the control of its native promoter.

Refers to a plasmid expression vector harboring the full-length cDNA (or truncations, as indicated) of Mdm2 under the control of the cytomegalovirus (CMV) promoter.

Refers to a plasmid expression vector harboring the full-length cDNA (or truncations, as indicated) of Mdm2 under the control of the murine stem cell virus (MSCV) promoter.

The observation that exogenous Mdm2 can prevent progression through the cell cycle suggests that Mdm2 may be functioning more like a tumor suppressor than an oncogene. Although these findings are at odds with data from earlier investigations, the methods used to drive Mdm2 overexpression have not been uniform. Groups that embraced an oncogenic role for Mdm2 reported differences in the transformation ability of the MDM2 cosmid versus cDNA expression plasmids in 3T3 cells.²¹ It is tempting to speculate that overexpression of genomic MDM2 may allow for an abundance of pro-transformation splice variants that are not permitted when full-length cDNA is employed. More than 40 distinct splice variants of mouse and human Mdm2 have been reported in a variety of tumors and cell lines, but their precise roles remain elusive.²² Many variants do not contain the binding site for p53, and several have been shown to inhibit proliferation following transfection of respective cDNA expression vectors into primary mouse embryo fibroblasts.²³ Similar antiproliferative effects were not seen in a p53^−/− setting, and it has been proposed that the relevant functions of full-length Mdm2 may be inhibited by these splice variants.²³ The increase in p53 stability that would be expected under these circumstances, however, is mechanistically inconsistent with an oncogenic role for these isoforms. Furthermore, it has yet to be determined whether all variant transcripts detected to date are actually translated into protein.

Many p53-independent functions of Mdm2 have been suggested in the wake of these findings. A role for Mdm2 in promoting S phase entry through its interactions with pRb and E2F1, for example, has been the subject of much study and is discussed below. Indeed, a growing body of work, including Mdm2 overexpression in vivo, suggests that the role of Mdm2 in neoplasia may not be as straightforward as once supposed (Table 2).

Table 2.

Selected Mouse Models of Mdm2 Overexpression

Study	Mouse Model(s)	Outcomes
Jones et al., 1998	Amplified genomic mdm2	Adult tissues with 4-fold Mdm2 overexpression.
		50% homozygotes developed tumors at 61 weeks.
		38% tumors in Mdm2-tg animals were sarcomas, as opposed to 9% in p53^–/– animals.
		No effect of p53 status on tumor latency or spectrum.
Lundgren et al., 1997²⁶	Targeted overexpression of mdm2 cDNA in the mouse mammary gland	10- to 30-fold increase in Mdm2 expression in mammary epithelial cells over wild-type controls.
		Mdm2-expressing mouse mammary epithelial cells had a high S phase index and were polyploid. Tumors seen after a latency of 14 to 18 months.
		Abnormal mammary gland development and tumor formation were independent of p53 and E2F1 status (Reinke et al.²⁷).
McDonnell et al., 1999²⁵	p53^–/–mdm2^–/–, p53^–/–mdm2^+/– p53^–/–mdm2^+/+	p53^–/–mdm2^+/– mice had a longer tumor latency and higher fraction of sarcomas over p53^–/–mdm2^+/+ or p53^–/–mdm2^–/– (45% vs 8% vs 10%).

Mice Overexpressing Mdm2 Develop Spontaneous Tumors along a Histopathologic Spectrum That Is Distinct from p53^−/− Mice and Display Phenotypes Independent of p53 Status

Jones et al.²⁴ described the effects of global overexpression of Mdm2 using an Mdm2-transgenic mouse line. The mouse was generated using the same genomic construct as that which had been used in early cell culture studies.^2,3 Blastocyst injections with clones of ES cells overexpressing MDM2 2-, 6-, 9-, and 15-fold were undertaken. Only those clones with 2-fold overexpression of MDM2 produced chimeric mice, however, despite the presence of 25 copies of the gene. This result suggests a possible selective pressure against a threshold level of MDM2 expression that may be incompatible with embryogenesis. Adult tissues, in contrast, demonstrated a 4-fold increase in MDM2 expression compared with wild-type controls.

The Mdm2-transgenic mice in this study developed tumors at an accelerated rate compared with wild-type mice. Mice homozygous for the transgene (MDM2^m1/m1) developed tumors more rapidly than their heterozygous counterparts (MDM2^m1/+; 50% developed neoplasia at 61 weeks vs 87 weeks, respectively), but both were slower than p53^−/− mice. No difference in tumor latency was observed in p53^−/− and MDM2^m1/m1p53^−/− animals. Most notable were the differences in tumor spectrum: MDM2^m1/m1 and MDM2^m1/m1p53^–/– developed a high fraction of sarcomas (38% sarcomas in both), in contrast to the predominance of lymphomas seen in p53^–/– mice (83% lymphomas, 9% sarcomas). Interestingly, a similar tumor latency and spectrum was observed in a separate study examining MDM2^+/–p53^–/– mice: p53^–/– mice that were heterozygous for MDM2 had a longer tumor latency and an increase in sarcomas compared with those that were either MDM2^+/+ or MDM2^−/− (45% sarcomas vs 8% and 10%, respectively).²⁵ Together, these studies support the possibility that Mdm2 may be playing a dose- and tissue-selective role in tumor formation.

A transgenic mouse with targeted overexpression of Mdm2 to the mammary gland has also been described.²⁶ To generate this mouse, investigators employed an MDM2 minigene construct (BLGMDM2) consisting of all exons and introns 7 and 8 of the MDM2 gene. Mdm2 overexpression was driven in a tissue-specific and hormonally regulated manner by the ovine BLG promoter. The minigene further allowed for detection of construct-specific transcripts by RNAse protection assay, the levels of which were compared with that of the endogenous full-length transcript to confirm relative overexpression of MDM2. Maximal expression of the transgene was observed during pregnancy and lactation and noted to be 10 to 30 times that of endogenous Mdm2. BLGMDM2 mice were found to exhibit abnormal mammary gland development and to develop multiple tumors in multiple mammary glands after a latency of 14 to 18 months. Mammary epithelial cells in BLGMDM2 mice demonstrated a high S phase index and polyploidy in both wild-type and p53^–/– backgrounds, suggesting that Mdm2 may be driving endoreplication in a p53-independent manner. This phenotype was subsequently shown to be independent of E2F1.²⁷ This finding is in contrast to studies in cells that have proposed a role for Mdm2 in controlling the G1-S cell cycle transition by virtue of its interactions with pRb and E2F1.^28-33

An Expanding Set of p53-Independent Functions Suggests Unique Contributions of Mdm2 Overexpression to Tumorigenesis

The ability to interact with the pRb-E2F1 complex and drive E2F1-dependent transcription and cell cycle progression was among the first p53-independent functions of Mdm2 to be proposed. An initial study showed that Mdm2 was able to directly bind E2F1 and its heterodimerization partner DP-1.²⁸ The interaction between Mdm2 and E2F1, but not Mdm2 and DP-1, was shown to stimulate E2F1 transcriptional activation by reporter assay, although a mechanism was not clear. These results, which were generated in a p53- and RB-null cell line (Saos2), further argued that the Mdm2-E2F1 relationship was independent of either p53 or pRb. A separate report, however, identified stable complexes between Mdm2 and the C-terminal region of pRb in an RB-replete cell line (U2OS) by co-immunoprecipitation.²⁹ In this study, co-transfection of Mdm2 into cells with a phosphorylation-resistant, hyperactive pRb mutant promoted endogenous E2F1 transcriptional activity and S phase entry that were both otherwise strongly inhibited. Similar results were obtained in a p53-null cell line, validating the p53-independent nature of this outcome. Although the authors did not rule out a role for a direct interaction between Mdm2 and E2F1, their findings argued that Mdm2 could directly prevent pRb suppression of E2F1 activity.

More recent efforts have attempted to elucidate the mechanism by which Mdm2 stimulates a G1-S transition through its interaction with either pRb or E2F1. Mdm2 preferentially binds hypophosphorylated pRb and is able to decrease recruitment of pRb-E2F1 complexes to DNA.³³ Failure to recruit pRb, a well-known transcriptional repressor, to promoters containing E2F sites may permit inappropriate upregulation of factors governing S phase entry.^34,35 Several groups have also shown that Mdm2 promotes the proteasomal degradation of pRb, although whether this outcome is dependent on the ability of Mdm2 to ubiquitinate pRb is not clear.^32,36,37 Other studies have suggested that Mdm2 controls the intracellular level of the E2F1-DP1 complex, perhaps by regulating binding of E2F1 to the SCF^Skp2 E3 ubiquitin ligase, so as to maintain levels below threshold that would otherwise trigger E2F1-dependent apoptosis in p53-null cells yet high enough to promote S phase entry.^30,31 Mdm2 may thus perturb the cellular response to oncogenic stress, for example, by optimizing levels of E2F1 and promoting a pro-survival, antiapoptotic response to this protein.

Mdm2 has since been shown to influence the level or function of several other proteins involved in cell cycle control and apoptosis independent of its effects on p53. For example, Mdm2 promotes the ubiquitin-dependent proteasomal degradation of the FOXO family of transcription factors, which regulate p27, cyclin D1, TRAIL, and other genes involved in cell proliferation and survival.³⁸ In addition, the ability of Mdm2 to selectively ubiqutinate Erk-phosphorylated FOXO3a suggests that Mdm2 overexpression may cooperate with activated mitogenic signaling cascades to promote tumorigenesis. Mdm2 can also interact with the IRES on the 5′-UTR of the mRNA encoding the antiapoptotic protein XIAP.³⁹ By enhancing the translation of XIAP, Mdm2 overexpression may blunt the apoptotic response to DNA damage and confer radioresistance.³⁹ Finally, Mdm2 can bind to and impair the function of Nbs1, a critical mediator of the DNA double-strand break repair response, delaying the resolution of DNA lesions and promoting genomic instability.⁴⁰

Mdm2 and Cancer: A Prognostic and Therapeutic Opportunity Leaps from Past to Present

Although several efforts have been made to correlate Mdm2 status with clinical outcomes in human cancers, the role of Mdm2 in sarcomas has been of particular interest. MDM2 amplification was originally demonstrated to occur in over one-third of human sarcomas, and these tumors were perhaps not surprisingly noted be more frequent in the Mdm2 transgenic mouse.^24,41-43 Interestingly, human tumor samples were found to harbor either MDM2 amplification or loss of p53, but not both. The authors concluded that amplification of MDM2 and subsequent Mdm2 overexpression represented an alternative but functionally synonymous means of p53 inactivation that might otherwise be seen in the setting of p53 loss. Of clinical interest, a separate study detected MDM2 amplification among either metastatic or recurrent osteosarcoma but not in any primary tumors analyzed.⁴⁴ Copy number alterations of MDM2, defined as the presence of greater than 3 copies of MDM2 in more than 10% of cells, have also been associated with poor response to chemotherapy in a larger study.⁴⁵ These and others reports suggest that high Mdm2 expression is a poor prognostic indicator in osteosarcoma.

Studies of Mdm2 in human tumors have been extended to other malignancies, but these reports have undercut the mutually exclusive relationship between MDM2 amplification and p53 mutation.^41,46-48 A unifying theme has been that Mdm2 overexpression need not occur exclusively in the setting of MDM2 amplification and that gene amplification does not necessarily result in detectable Mdm2 overexpression. For example, Watanabe et al.⁴⁷ failed to detect MDM2 amplifications in any of 17 B-cell leukemias or lymphomas that had greater than 10-fold overexpression of Mdm2 by Northern blotting and immunohistochemical staining (IHC). Cordon-Cardo et al.⁴⁶ noted that 5 of 11 soft tissue sarcomas with MDM2 amplification had IHC-undetectable Mdm2, whereas 17 of 62 sarcomas negative for MDM2 amplification were positive for Mdm2 by IHC.

Taken together, studies addressing Mdm2 in human tumors present contradictory clinical implications of its overexpression across a broad spectrum of malignancies.⁴⁸ One concern is the use of IHC to detect either Mdm2 or p53, particularly due to the use of different antibodies to Mdm2. Total Mdm2 protein levels assessed in this manner may not account for mutant or alternatively or aberrantly spliced Mdm2. Attempts to assign a prognostic value to Mdm2 overexpression alone and in the setting of p53 mutation are also complicated by this approach. The use of elevated protein levels of p53 as a surrogate marker of p53 mutation that has lead to loss of function does not account for potential gain-of-function effects of certain p53 mutations.⁴⁹ In addition, the functional equivalence of Mdm2 overexpression and loss of p53 need to be more thoroughly investigated. For example, even abnormally high levels of Mdm2 may abrogate p53 activity under basal conditions but should nevertheless be disengaged under genotoxic stress. The dynamic interplay between Mdm2 and p53 makes it difficult to accommodate a model of tumorigenesis in which Mdm2 inactivates the p53 pathway solely by virtue of its overexpression. It seems more plausible that there are effects of Mdm2 overexpression that do not mimic loss of p53. Indeed, the many p53-independent functions of Mdm2 speak to the need to consider that these separate lesions do not represent comparable pathways of p53 inactivation.

It has been proposed that therapies targeting the interaction between Mdm2 and p53 represent a possible means of pharmacologically reactivating the p53 pathway, and a number of such agents are currently in clinical trials.^50,51 A more thorough understanding of the consequences of Mdm2 overexpression, particularly those that are independent of its roles as a regulator of p53, will greatly inform this therapeutic strategy.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

Cahilly-Snyder

Yang-Feng

Francke

George

. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet. 1987;13(3):235-44.

Fakharzadeh

Trusko

George

. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. Embo J. 1991;10(6):1565-9.

Finlay

. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol. 1993;13(1):301-6.

Momand

Zambetti

Olson

George

Levine

. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69(7):1237-45.

Chen

Lin

Levine

. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol. 1996;16(5):2445-52.

Haupt

Maya

Kazaz

Oren

. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387(6630):296-9.

Kubbutat

Jones

Vousden

. Regulation of p53 stability by Mdm2. Nature. 1997;387(6630):299-303.

Honda

Tanaka

Yasuda

. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997;420(1):25-7.

Marine

Dyer

Jochemsen

. MDMX: from bench to bedside. J Cell Sci. 2007;120(Pt 3):371-8.

10.

Wade

Wang

Wahl

. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 2010;20(5):299-309.

11.

Kruse

. Modes of p53 regulation. Cell. 2009;137(4):609-22.

12.

Sherr

. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer. 2006;6(9):663-73.

13.

Zhang

. Signaling to p53: ribosomal proteins find their way. Cancer Cell. 2009;16(5): 369-77.

14.

Barak

Juven

Haffner

Oren

. Mdm2 expression is induced by wild type p53 activity. Embo J. 1993;12(2):461-8.

15.

Gajjar

Candeias

Malbert-Colas

.The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell. 2012;21(1):25-35.

16.

Candeias

Malbert-Colas

Powell

.P53 mRNA controls p53 activity by managing Mdm2 functions. Nat Cell Biol. 2008; 10(9):1098-105.

17.

Montes de Oca Luna

Wagner

Lozano

. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995;378(6553):203-6.

18.

Jones

Roe

Donehower

Bradley

. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995;378(6553):206-8.

19.

Brown

Thomas

Deb

. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. Embo J. 1998;17(9):2513-25.

20.

Schlott

Reimer

Jahns

.Point mutations and nucleotide insertions in the MDM2 zinc finger structure of human tumours. J Pathol. 1997;182(1):54-61.

21.

de Oca Luna

Tabor

Eberspaecher

.The organization and expression of the mdm2 gene. Genomics. 1996;33(3):352-7.

22.

Bartel

Taubert

Harris

. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell. 2002;2(1):9-15.

23.

Dang

Kuo

Eischen

Stepanova

Sherr

Roussel

. The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res. 2002;62(4):1222-30.

24.

Jones

Hancock

Vogel

Donehower

Bradley

. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA. 1998;95(26):15608-12.

25.

McDonnell

Montes de Oca Luna

Cho

Amelse

Chavez-Reyes

Lozano

. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol. 1999;188(3):322-8.

26.

Lundgren

Montes de Oca Luna

McNeill

.Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev. 1997;11(6):714-25.

27.

Reinke

Bortner

Amelse

.Overproduction of MDM2 in vivo disrupts S phase independent of E2F1. Cell Growth Differ. 1999;10(3):147-54.

28.

Martin

Trouche

Hagemeier

Sorensen

La Thangue

Kouzarides

. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature. 1995;375(6533):691-4.

29.

Xiao

Chen

Levine

.Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature. 1995;375(6533):694-8.

30.

Loughran

La Thangue

. Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol Cell Biol. 2000;20(6):2186-97.

31.

Zhang

Wang

Rayburn

Agrawal

Zhang

. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene. 2005;24(48):7238-47.

32.

Sdek

Ying

Chang

.MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell. 2005;20(5):699-708.

33.

Sdek

Ying

Zheng

.The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth. J Biol Chem. 2004;279(51):53317-22.

34.

Stevaux

Dyson

. A revised picture of the E2F transcriptional network and RB function. Curr Opin Cell Biol. 2002;14(6):684-91.

35.

Zhu

. Tumour suppressor retinoblastoma protein Rb: a transcriptional regulator. Eur J Cancer. 2005;41(16):2415-27.

36.

Miwa

Uchida

Kitagawa

.Mdm2-mediated pRB downregulation is involved in carcinogenesis in a p53-independent manner. Biochem Biophys Res Commun. 2006;340(1):54-61.

37.

Uchida

Miwa

Kitagawa

.Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J. 2005;24(1):160-9.

38.

Chen

.MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J Biol Chem. 2009;284(21):13987-4000.

39.

Zhu

Zhang

Durden

Feng

Zhou

. Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell. 2009;15(5):363-75.

40.

Bouska

Eischen

. Mdm2 affects genome stability independent of p53. Cancer Res. 2009;69(5):1697-701.

41.

Momand

Jung

Wilczynski

Niland

. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26(15):3453-9.

42.

Oliner

Kinzler

Meltzer

George

Vogelstein

. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992;358(6381):80-3.

43.

Leach

Tokino

Meltzer

.p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993;53(10, Suppl):2231-4.

44.

Ladanyi

Cha

Lewis

Jhanwar

Huvos

Healey

. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res. 1993;53(1):16-8.

45.

Duhamel

Halai

.Frequency of Mouse Double Minute 2 (MDM2) and Mouse Double Minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes. Histopathology. 2012;60(2):357-9.

46.

Cordon-Cardo

Latres

Drobnjak

.Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994;54(3):794-9.

47.

Watanabe

Hotta

Ichikawa

.The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood. 1994;84(9):3158-65.

48.

Rayburn

Zhang

Wang

. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets. 2005;5(1):27-41.

49.

Goh

Coffill

Lane

. The role of mutant p53 in human cancer. J Pathol. 2011;223(2): 116-26.

50.

Millard

Pathania

Grande

Neamati

. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update. Curr Pharm Des. 2011;17(6):536-59.

51.

Vassilev

. Small-molecule inhibitors of the p53-MDM2 interaction. Curr Top Microbiol Immunol. 2011;348:151-72.

Mdm2 and Tumorigenesis

Abstract

Keywords

Introduction

Modeling Mdm2 Overexpression in Cells: Different Contexts, Different Methods, and Contradictory Conclusions

Mice Overexpressing Mdm2 Develop Spontaneous Tumors along a Histopathologic Spectrum That Is Distinct from p53−/− Mice and Display Phenotypes Independent of p53 Status

An Expanding Set of p53-Independent Functions Suggests Unique Contributions of Mdm2 Overexpression to Tumorigenesis

Mdm2 and Cancer: A Prognostic and Therapeutic Opportunity Leaps from Past to Present

Footnotes

Declaration of Conflicting Interests

Funding

References

Mice Overexpressing Mdm2 Develop Spontaneous Tumors along a Histopathologic Spectrum That Is Distinct from p53^−/− Mice and Display Phenotypes Independent of p53 Status